Evaluating the Use of the Qidni/D Hemodialysis System by Subjects With End-Stage Renal Disease

Kidney Disease, End-Stage Clinical Trial

Official title:
A Prospective Single-Center, Open Label, Non-Randomized Study Evaluating the Use of the Qidni/D Hemodialysis System by Subjects With End-Stage Renal Disease

Status Recruiting

Clinical Trial Summary

The main goal of this clinical study is to evaluate the safety of the Qidni/D Hemodialysis System in patients with end-stage renal disease. The main question it aims to answer is: Is the Qidni/D safe for performing hemodialysis? Participants will be subjected to one treatment of hemodialysis for up to 4 hours with the use of the Qidni/D.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT06086470
Study type	Interventional
Source	Qidni Labs Inc.
Contact	Morteza Ahmadi, PhD
Phone	2266060956
Email	ma@qidni.com
Status	Recruiting
Phase	N/A
Start date	May 1, 2023
Completion date	July 14, 2024

View Details

See also
Status	Clinical Trial	Phase
Withdrawn	`NCT04665310` - Evaluation of Anti-rejection Drug, Tacrolimus, in African-Americans With Kidney Transplant	Phase 4
Completed	`NCT02964429` - Determination In-vivo KUF for Diacap Pro Hemodialyser	N/A
Recruiting	`NCT04634916` - Post-market Surveillance Study of the BD® WavelinQ™ EndoAVF System	N/A
Not yet recruiting	`NCT06089473` - Virtual Home-based Physical Pre-habilitation in Kidney Transplant Candidates	N/A
Completed	`NCT03149328` - Electronic Patient-Reported Outcomes in Clinical Kidney Practice (ePRO Kidney)	N/A
Active, not recruiting	`NCT04484220` - Ellipsys Vascular Access System Post Market Surveillance (PS) Study	N/A